A team of researchers has now engineered a virus nanoparticle vaccine against Bacillus anthracis and Yersinia pestis, tier 1 agents that pose serious threats to national security of the United States.
B. anthracis and Y. pestis are the pathogens that cause anthrax and plague, respectively.
Using bacteriophage T4, the scientists developed the vaccine by incorporating key antigens of both B. anthracis and Y. pestis into one formulation.
Two doses of this vaccine provided complete protection against both inhalational anthrax and pneumonic plague in animal models.
Even when animals were threatened with lethal doses of both anthrax lethal toxin and Y. pestis CO92 bacteria, the vaccine was shown to be effective.
The study is published in mBio, an open-access journal of the American Society for Microbiology. The authors summarized the potential applications of their work:
“This dual anthrax-plague vaccine is a strong candidate for stockpiling against a potential bioterror attack involving either one or both of these biothreat agents.”Their results demonstrate that T4 nanoparticle is a novel platform for developing multivalent vaccines against pathogens of high public health concern.
This article has been republished from materials provided by the American Society for Microbiology. Note: material may have been edited for length and content. For further information, please contact the cited source.
Tao, P., Mahalingam, M., Zhu, J., Moayeri, M., Sha, J., Lawrence, W. S., . . . Rao, V. B. (2018). A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. MBio, 9(5). doi:10.1128/mbio.01926-18